Printer Friendly

TELECONCEPTS COMPLETES ACQUISITION OF RIGHTS TO MARKET FDA-APPROVED CONFIRMATION AND SCREENING TEST FOR AIDS

 TELECONCEPTS COMPLETES ACQUISITION OF RIGHTS TO MARKET FDA-APPROVED
 CONFIRMATION AND SCREENING TEST FOR AIDS
 HOUSTON, Oct. 5 /PRNewswire/ -- TeleConcepts Corporation (AMEX: TCC) today announced that it has completed the acquisition of the exclusive license rights to market and sell Fluorognost HIV-1 IFA in the United States and Canada from TBL Diagnostics, Inc., a privately held Delaware corporation. As result of its entry into the medical diagnostic business, TeleConcepts will change its name to Virology Testing Sciences, Inc.
 Fluorognost HIV-1 IFA is an FDA-approved confirmation and screening test which is used to detect antibodies to Human Immunodeficiency Virus Type 1 ("HIV-1") in human blood serum or plasma. HIV-1 is a virus that causes Acquired Immune Deficiency Syndrome ("AIDS"). Thermascan, Inc. (OTC: THEM) held the marketing rights to Fluorognost until 1989, when it assigned its rights (subject to certain retained contingent rights) to a predecessor of TBL as security for loans to be used by Thermascan to fund their efforts to secure FDA licensing, which license was granted on Feb. 5, 1992.
 On Sept. 15, 1992, Thermascan terminated its previously announced merger with TeleConcepts, and on Sept. 18, 1992, TeleConcepts filed suit in Texas state court against Thermascan (although it has not yet served Thermascan), alleging breach of contract and seeking, among other relief, liquidated and unliquidated damages. Both prior and subsequent to the filing of the lawsuit, TeleConcepts was engaged in negotiations with Thermascan seeking to revive the merger, but negotiations broke off Sept. 30. As a result, TeleConcepts is not now merging with Thermascan and therefore will not now be issuing approximately 8,100,000 shares of its common stock to the common and preferred shareholders of Thermascan.
 Nevertheless, TeleConcepts is considering efforts to resume negotiations that could lead to a merger or other acquisition, although no assurances can be given in this regard. TeleConcepts, however, will continue to market and sell Fluorognost under the rights it has acquired from TBL.
 On July 31, 1992, TeleConcepts agreed to acquire TBL's rights to market Fluorognost for $834,000 in cash ($417,000 of which was paid on July 31 and $417,000 of which was paid on Oct. 2), $417,000 of short- term notes due Nov. 30, 1992 (which accrue interest at an annual rate of 12 percent), and two series of cumulative convertible preferred stock (which will be issued on or before Nov. 30, 1992) with an aggregate liquidation preference of $1,661,000, $857,000 of which is senior and carries a 12 percent annual dividend rate and $804,000 of which carries a 7 percent annual dividend rate. The rights will be held in escrow pending the satisfaction of certain conditions, but under the agreement with TBL, TeleConcepts will be entitled to the financial benefits under the rights while they are subject to the escrow. Moreover, Thermascan has certain contingent residual rights to the license under existing agreements.
 As previously announced, TeleConcepts has determined not to proceed with the spin-off of its subsidiary which designs and markets telephones and telephone devices for residential and commercial use. TeleConcepts still will issue to TeleConcepts stockholders of record as of Oct. 12, 1992, one warrant to purchase one share of TeleConcepts common stock for every two shares they hold, exercisable for three years at 110 percent of the average closing price for the ten trading days subsequent to the record date. The warrants shall be redeemable by TeleConcepts at a price of $0.10 per warrant if the closing price of TeleConcepts common stock has exceeded 125 percent of the exercise price on ten consecutive trading days.
 -0- 10/5/92
 /CONTACT: Holly G. Vaughan of TeleConcepts Corporation, 713-228-4633/
 (TCC) CO: TeleConcepts Corporation; TBL Diagnostics, Inc. ST: Texas IN: MTC SU:


LR-OS -- NY026 -- 6480 10/05/92 10:12 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 5, 1992
Words:630
Previous Article:LOWRY ASSOCIATES, INC., SUBSIDIARY OF USF&G, ACQUIRED IN M.B.O. BY EMPLOYEE GROUP
Next Article:SHAWMUT NATIONAL CORPORATION INTRODUCES BILL-LINE A TELEPHONE-BASED BILL-PAYING SERVICE
Topics:


Related Articles
THERMASCAN STATEMENT ON UNRESOLVED HIV-1 ANTIBODY STATUS
TELECONCEPTS SETS NEW DATE FOR SPECIAL MEETING TO APPROVE MERGER WITH THERMASCAN - PRIVATE PLACEMENT FULLY COMMITTED
THE JOURNAL OF CLINICAL MICROBIOLOGY REPORTS THAT A NEW FDA-APPROVED AIDS TEST WILL IMPROVE SPECIFICITY OF HIV CONFIRMATORY TESTING
THERMASCAN STOCKHOLDERS APPROVE MERGER WITH TELECONCEPTS
VIROLOGY TESTING SCIENCES, INC. ANNOUNCES NEW HIV-2 CONFIRMATION AND SCREENING TEST
VIRAL TESTING SYSTEMS WILL FOCUS ON THE ONLY FDA APPROVED TEST THAT CAN BOTH SCREEN AND CONFIRM FOR HIV
VIRAL TESTING SYSTEMS WILL FOCUS ON THE ONLY FDA APPROVED TEST THAT CAN BOTH SCREEN AND CONFIRM FOR HIV; DR. HERMANN MUCKE WILL HEAD R&D
EDITEK LAUNCHES EZ-SCREEN(R) PROFILE(TM) DRUGS OF ABUSE PRODUCT
American Cancer Society Publishes Cervical Cancer Screening Guidelines Supporting HPV Testing.
New Study in 'JAMA' Supports Use of Digene's HPV Test As Primary Cervical Cancer Screen.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters